{
  "docId": "019de072-118b-7459-8ccb-22724833fcd4",
  "docSlug": "04de07fbea9eadeda44cc99f91069101",
  "documentTitle": "AbCellera | Results Presentation Deck | 21 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 21,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "sparse",
  "nDataPoints": 6,
  "notes": "The chart uses a logarithmic-style vertical axis to show potency differences, with Bebtelovimab as the baseline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-118b-7459-8ccb-22724833fcd4/12",
  "deckHref": "/decks/019de072-118b-7459-8ccb-22724833fcd4",
  "deckJsonHref": "/decks/019de072-118b-7459-8ccb-22724833fcd4.json",
  "deckAnchorHref": "/decks/019de072-118b-7459-8ccb-22724833fcd4#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.85,
        "x": 0.105,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Potency comparison chart",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc5daea8-bee9-46ec-a632-47a9dd6ab676",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.35,
        "y": 0.57
      },
      "kind": "source-note",
      "text": "*against Omicron, relative to bebtelovimab",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62d5e333-c29b-42ba-9ed4-48e8372a8114",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.105,
        "y": 0.045
      },
      "kind": "title",
      "text": "BEBTELOVIMAB IS THE MOST POTENT ANTIBODY IN DEVELOPMENT AGAINST THE OMICRON VARIANT.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fe59e5d-761c-4838-ae3e-2b8960340174",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "5b671459-a01d-43ff-bac9-167a12068da8",
      "evidence": "chart/dot: Potency comparison chart",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "78eff05a-cc1e-4ca9-aaf4-e9f0121492f8",
      "evidence": "Direct comparison of potency metrics across multiple competitive products.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 13,
      "from": 7,
      "beatId": "bf52f0f4-f71c-45d7-83ba-6d61d5147353",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases the company's strong growth in royalty rates, flexible deal structures, and advancements in GPCRs, ion channels & bispecific antibodies.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "c116a9b9-66b9-474f-8411-60fed0150046",
      "evidence": "The presentation explains the company's technology and its applications.",
      "position": 0,
      "objective": "Why AbCellera's technology is important for antibody discovery",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 13,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "18b38177-33a6-4a4b-86ec-5de8ccd482e5",
      "evidence": "The presentation highlights the benefits of partnering with AbCellera.",
      "position": 1,
      "objective": "The potential consequences of not partnering with AbCellera",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}